Search bioRxiv⌕ Search

Biology subjects

Chumakov, K.

Publications and source records attributed to Chumakov, K..

3 recordsLinked to original sources

Imprinted antibody lineages can persist for half a century and dominate cross-neutralizing recall responses to poliovirus

Humoral immunity depends on a dynamic interplay between circulating polyclonal IgG antibodies and long-lived memory B cells (MBC). To elucidate this relationship, we integrated B-cell receptor sequencing with plasma IgG immunoproteomics to identify and quantify the recall response (plasma IgG and MBC) to inactivated poliovirus vaccine (IPV) in eight adults, 24-55 years after their childhood immunization. IPV immunization elicited highly skewed plasma IgG recall repertoires, dominated by a small subset ([~]8%) of total antibody lineages that were detectable prior to boosting (i.e., "pre-existing"). These IgG lineages spiked logarithmically in abundance ([~]102-104 fold-increase) and potently cross-neutralized multiple PV serotypes in vitro (titers [≥] 1:105). Notably, these dominant plasma IgG lineages were clonally linked to class-switched MBCs that circulated in blood 21 days post-boost and bore heavily mutated VH and VL variable region genes. Importantly, IPV-primed ex vivo B-cell cultures (MIMIC, Modular IMmune In vitro Construct) yielded clonal expansions that mirrored the dominant post-boost plasma IgG lineages in vivo, providing an in vitro mechanistic correlate of recall immunity. Together these findings demonstrate a decades-long interconnectivity between persistent MBC clones and the serological IgG repertoire. They further highlight the central role of immunological imprinting, whereby cross-reactive MBC clones--originally primed in childhood--can be reactivated to dominate the circulating IgG recall response more than 50 years after initial exposure.

immunology↗

Towards the development of a mucosal vectored vaccine against enterovirus D68

Enterovirus D68 (EVD68) is an emerging pathogen associated with neurological complications, including temporary and permanent paralysis, and lethality. Currently, no EVD68-specific vaccines or antivirals are available. Here, we used a Newcastle disease virus (NDV) vector to develop a live mucosal vaccine that produces EVD68 virus-like particles (VLPs) and evaluated its immunogenicity in a murine model. We made constructs producing VLPs of the prototype EVD68 strain Fermon and the USA/2018-23088 (Ohio-2018) strain from a recent outbreak in the USA. Our results demonstrate robust production and proper processing of EVD68 capsid proteins upon co-expression with the viral protease 3CD. Intranasally-immunized animals effectively seroconverted to NDV antigens, indicating successful replication of the vectors. Antibodies that could bind both the Fermon and Ohio-2018 virions were observed in the sera of mice immunized with either viral vector. At least some animals also demonstrated a strong respiratory mucosal IgA response against EVD68 capsid proteins. These data confirm the immunogenicity of EVD68 proteins expressed from a viral vector in the respiratory tract. Yet neither humoral nor mucosal antibodies were protective against EVD68 infection in cell culture. Analysis of cells infected with recombinant NDVs by electron microscopy indicated structural differences between bona fide EVD68 virions and VLPs, suggesting that the lack of neutralizing antibody response is likely due to antigenic disparity between the EVD68 virions and empty VLPs and/or limited stability of VLPs within the murine respiratory tract. These results have important implications for the development of VLP-based vaccines against enteroviruses.

microbiology↗

Viral vector-driven trans-encapsidation of replicon RNAs as a rapid approach for the development of safe and economically attractive anti-enterovirus vaccines

Multiple enteroviruses are associated with life-threatening and economically important diseases, yet licensed vaccines are available only against poliovirus (worldwide) and enterovirus A71 (China). Both live attenuated and inactivated anti-poliovirus vaccines, while highly successful in preventing the disease, have important shortcomings. Live vaccine strains are inherently genetically unstable and can regain virulence, leading to re-emergence of paralytic disease. Inactivated vaccine does not induce the mucosal immunity sufficient to interrupt viral transmission and is made from virulent strains, presenting a biosafety challenge. Recent alternatives, such as new vaccine strains with improved genetic stability and VLP-based vaccines, only partially address these concerns. Here, we investigated another approach to the development of anti-enterovirus vaccines based on efficient trans-encaspidation of replication-competent enterovirus RNAs coding for only the non-structural proteins (replicons) by Newcastle Disease virus vectors expressing enterovirus capsid proteins. Thus, the encapsidated replicon production is driven by effectively replicating enterovirus RNA and the NDV vector. This system is easily scalable and can be adapted to any cell culture provided it can be infected by both the enterovirus and NDV. Unlike the empty VLPs, the encapsidated replicons recapitulate the stability and antigenicity of native enterovirus particles, but cannot propagate beyond the originally infected cell. The protective efficacy of an encapsidated poliovirus replicon immunization was similar to that of the licensed Sabin vaccine strain in a murine model. This approach can easily be adapted to any enterovirus, allowing the rapid development of new, affordable vaccine candidates.

microbiology↗